Davis Jason
Known title: Chief Financial OfficerCIK: 0001443533
Davis Jason's purchase track record
Davis Jason has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/2/2026 | FBLG | $29K | -86.7% | -79.8% | +11.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| FBLG | ▲ Buy | Open Market | 70,000 | $29K | 3/2/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
FibroBiologics Secures European Patent for Fibroblast Methods
FibroBiologics announced the grant of a European patent for methods enhancing fibroblast therapeutic activity. This development strengthens the company's intellectual property portfolio in Europe. The stock is currently trading near its 52-week low, significantly below the average analyst target price.
FibroBiologics Secures European Patent for Fibroblast Methods. FibroBiologics announced the grant of a European patent for methods enhancing fibroblast therapeutic activity. This development strengthens the company's intellectual property portfolio in Europe. The stock is currently trading near its 52-week low, significantly below the average analyst target price.